Rachel L Tomko1, Nathaniel L Baker2, Erin A McClure3, Susan C Sonne3, Aimee L McRae-Clark3, Brian J Sherman3, Kevin M Gray3. 1. Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, United States. Electronic address: tomko@musc.edu. 2. Department of Public Health Sciences, Medical University of South Carolina, United States. 3. Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, United States.
Abstract
BACKGROUND: Quantifying cannabis use is complex due to a lack of a standardized packaging system that contains specified amounts of constituents. A laboratory procedure has been developed for estimating physical quantity of cannabis use by utilizing a surrogate substance to represent cannabis, and weighing the amount of the surrogate to determine typical use in grams. METHOD: This secondary analysis utilized data from a multi-site, randomized, controlled pharmacological trial for adult cannabis use disorder (N=300), sponsored by the National Drug Abuse Treatment Clinical Trials Network, to test the incremental validity of this procedure. In conjunction with the Timeline Followback, this physical scale-based procedure was used to determine whether average grams per cannabis administration predicted urine cannabinoid levels (11-nor-9-carboxy-Δ9-tetrahydrocannabinol) and problems due to use, after accounting for self-reported number of days used (in the past 30 days) and number of administrations per day in a 12-week clinical trial for cannabis use disorder. RESULTS: Likelihood ratio tests suggest that model fit was significantly improved when grams per administration and relevant interactions were included in the model predicting urine cannabinoid level (X2=98.3; p<0.05) and in the model predicting problems due to cannabis use (X2=6.4; p<0.05), relative to a model that contained only simpler measures of quantity and frequency. CONCLUSIONS: This study provides support for the use of a scale-based method for quantifying cannabis use in grams. This methodology may be useful when precise quantification is necessary (e.g., measuring reduction in use in a clinical trial).
BACKGROUND: Quantifying cannabis use is complex due to a lack of a standardized packaging system that contains specified amounts of constituents. A laboratory procedure has been developed for estimating physical quantity of cannabis use by utilizing a surrogate substance to represent cannabis, and weighing the amount of the surrogate to determine typical use in grams. METHOD: This secondary analysis utilized data from a multi-site, randomized, controlled pharmacological trial for adult cannabis use disorder (N=300), sponsored by the National Drug Abuse Treatment Clinical Trials Network, to test the incremental validity of this procedure. In conjunction with the Timeline Followback, this physical scale-based procedure was used to determine whether average grams per cannabis administration predicted urine cannabinoid levels (11-nor-9-carboxy-Δ9-tetrahydrocannabinol) and problems due to use, after accounting for self-reported number of days used (in the past 30 days) and number of administrations per day in a 12-week clinical trial for cannabis use disorder. RESULTS: Likelihood ratio tests suggest that model fit was significantly improved when grams per administration and relevant interactions were included in the model predicting urine cannabinoid level (X2=98.3; p<0.05) and in the model predicting problems due to cannabis use (X2=6.4; p<0.05), relative to a model that contained only simpler measures of quantity and frequency. CONCLUSIONS: This study provides support for the use of a scale-based method for quantifying cannabis use in grams. This methodology may be useful when precise quantification is necessary (e.g., measuring reduction in use in a clinical trial).
Authors: Thomas Nadulski; Fritz Pragst; Gordon Weinberg; Patrik Roser; Martin Schnelle; Eva-Maria Fronk; Andreas Michael Stadelmann Journal: Ther Drug Monit Date: 2005-12 Impact factor: 3.681
Authors: Kevin M Gray; Susan C Sonne; Erin A McClure; Udi E Ghitza; Abigail G Matthews; Aimee L McRae-Clark; Kathleen M Carroll; Jennifer S Potter; Katharina Wiest; Larissa J Mooney; Albert Hasson; Sharon L Walsh; Michelle R Lofwall; Shanna Babalonis; Robert W Lindblad; Steven Sparenborg; Aimee Wahle; Jacqueline S King; Nathaniel L Baker; Rachel L Tomko; Louise F Haynes; Ryan G Vandrey; Frances R Levin Journal: Drug Alcohol Depend Date: 2017-06-10 Impact factor: 4.492
Authors: Tom P Freeman; Celia J A Morgan; Chandni Hindocha; Gráinne Schafer; Ravi K Das; H Valerie Curran Journal: Addiction Date: 2014-07-16 Impact factor: 6.526
Authors: Rachel L Tomko; Nathaniel L Baker; Caitlyn O Hood; Amanda K Gilmore; Erin A McClure; Lindsay M Squeglia; Aimee L McRae-Clark; Susan C Sonne; Kevin M Gray Journal: Psychopharmacology (Berl) Date: 2019-11-11 Impact factor: 4.530
Authors: Rachel L Tomko; Kevin M Gray; Marilyn A Huestis; Lindsay M Squeglia; Nathaniel L Baker; Erin A McClure Journal: Curr Addict Rep Date: 2019-11-19
Authors: Danielle C Hergert; Cidney Robertson-Benta; Veronik Sicard; Daniela Schwotzer; Kent Hutchison; Dan P Covey; Davin K Quinn; Joseph R Sadek; Jacob McDonald; Andrew R Mayer Journal: J Neurotrauma Date: 2021-01-25 Impact factor: 4.869
Authors: Natasha E Wade; Rachel Baca; Kelly E Courtney; Connor J McCabe; M Alejandra Infante; Marilyn A Huestis; Joanna Jacobus Journal: J Int Neuropsychol Soc Date: 2021-07 Impact factor: 2.892
Authors: Hugo López-Pelayo; Silvia Matrai; Mercè Balcells-Olivero; Eugènia Campeny; Fleur Braddick; Matthijs G Bossong; Olga S Cruz; Paolo Deluca; Geert Dom; Daniel Feingold; Tom P Freeman; Pablo Guzman; Chandni Hindocha; Brian C Kelly; Nienke Liebregts; Valentina Lorenzetti; Jakob Manthey; João Matias; Clara Oliveras; Maria Teresa Pons; Jürgen Rehm; Moritz Rosenkranz; Zoe Swithenbank; Luc van Deurse; Julian Vicente; Mike Vuolo; Marcin Wojnar; Antoni Gual Journal: Front Psychiatry Date: 2021-05-20 Impact factor: 4.157
Authors: Brian J Sherman; Michael J Sofis; Jacob T Borodovsky; Kevin M Gray; Aimee L McRae-Clark; Alan J Budney Journal: Psychol Addict Behav Date: 2021-07-01